Form 8-K

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
____________________
 
Date of report (Date of earliest event reported): March 30, 2007
 
Applied DNA Sciences, Inc
(Exact Name of Registrant as Specified in Charter)
 
Nevada
(State or Other Jurisdiction
of Incorporation)
002-90539
(Commission File Number)
59-2262718
(IRS Employer
Identification No.)
 
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
(Address of Principal Executive Offices) (Zip Code)
 
 
631-444-6861
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 

o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


Item 8.01 Other Events.

On April 4, 2007, Applied DNA Sciences, Inc. (the “Company”) issued a press release to announce that the parties to the Sub-License Agreement dated July 29, 2003, by and between the Company, Biowell Technology, Inc. and G.A. Corporate Finance Ltd., have terminated such Sub-License Agreement, and that in connection with such termination all of G.A. Corporate Finance Ltd.’s interests in Applied DNA Sciences Europe Ltd. have been transferred to the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits
 

 
(d)
Exhibits.
 
 
Exhibit 99.1
Press release of Applied DNA Sciences, Inc., dated April 4, 2007.



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 

 
Applied DNA Sciences, Inc.
 
(Registrant)
   
   
   
 
By: /s/ James Hayward                       
 
James Hayward
 
Chief Executive Officer
   
Date: April 4, 2007
  
 
 
 
 
 
Exhibit No.
 
Description of Exhibit
     
99.1   Press Release of Applied DNA Sciences, Inc., dated April 4, 2007.